Q2 2025 Heron Therapeutics Inc Earnings Call Transcript
Key Points
- Heron Therapeutics Inc (HRTX) successfully completed a new financing, strengthening its balance sheet and enhancing financial flexibility.
- The company reported strong operational and financial performance with total net revenues of $37.2 million for the quarter and $76.1 million for the first half of 2025.
- Heron Therapeutics Inc (HRTX) achieved a significant milestone with the transition from a C code to a permanent J code for Zenerlef, effective October 1, which is expected to streamline reimbursement processes.
- The oncology franchise outperformed expectations with combined net revenues from Symvanti and Sostall reaching $26.5 million for the quarter.
- The company reported a net income of $300,000 for the first half of 2025, compared to a net loss of $12.4 million for the same period in 2024.
- Q2 revenue was impacted by a transient inventory drawdown at wholesalers, reducing net sales by approximately $400,000.
- Despite strong demand growth, reported revenue was relatively flat quarter over quarter due to inventory normalization and standard 340B discounts.
- SG&A expenses remained high at $26 million for the quarter, although slightly reduced from the previous year.
- Research and development expenses decreased, but this was primarily due to terminations and write-offs rather than increased efficiency.
- The company incurred a net loss of $2.4 million for the three months ended June 30, 2025, despite improvements compared to the previous year.
Thank you for standing by and welcome to the Huron Therapeutics Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakersâ presentation, there will be a question and answer session. To ask a question during this session, youâll need to press 11 on your telephone. If your question has been answered and youâd like to remove yourself from the queue, simply press 11 again.
As a reminder, todayâs program is being recorded. And now Iâd like to introduce your host for todayâs program, Melissa Jarrell, Executive Director of Legal at Huron. Please go ahead.
Thank you, operator, and hello, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the companyâs financial results for the quarter ended 06/30/2025. With me today from Heron are Craig Collard, Chief Executive Officer Ira Duarte, Executive Vice President, Chief Financial Officer Bill Forbes, Executive Vice President,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
